Business · 07/10/2022Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Rare Pediatric Disease Product Applicant
Summary
The FDA has awarded a priority review voucher to bluebird bio, Inc. for its rare pediatric disease product application, SKYSONA, which is manufactured by the company and meets the criteria set by the Federal Food, Drug, and Cosmetic Act.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →